idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of tumour-related deaths. This is due to late diagnosis and the rapid spread of tumour cells throughout the body. In two international clinical trials, a team of scientists involving the University of Leipzig Medical Center have investigated a drug that can prolong patients’ survival. Thanks to the recently published data, zolbetuximab has now been approved as a drug in Europe. Patients with gastric cancer are expected to be able to be treated with it in Germany from the end of this year. The results have been published in The New England Journal of Medicine.
“The results of these trials are very important for cancer research. They show that patients with advanced gastric cancer treated with zolbetuximab live longer. The progression of the disease is delayed. This is an important step forward for patients suffering from this serious and often fatal cancer,” says Professor Florian Lordick, Director of the University Cancer Center Leipzig. The experienced oncologist was involved in the international design of the recently published trials and ensured that German patients were able to participate.
“We were able to offer the drug zolbetuximab early on in clinical trials at the University of Leipzig Medical Center. We treated many patients with advanced gastric cancer and reported positive results. We are now delighted that a targeted therapy with zolbetuximab has been approved by the European Medicines Agency following large phase III trials,” says Professor Lordick.
In the two trials, a total of 1072 patients worldwide were treated with zolbetuximab or a placebo. The results show that people with advanced gastric cancer who received zolbetuximab plus chemotherapy survived longer than those who received chemotherapy alone. In this research, treatment with zolbetuximab and chemotherapy significantly reduced the risk of disease progression and death by 29 per cent.
All participants in the trials had gastric cancer with increased expression of the protein claudin 18.2. Zolbetuximab is an antibody that specifically targets the claudin 18.2. Around one in three patients have high levels of claudin 18.2 in their gastric cancer, but it is rarely found in healthy tissue outside the stomach, making it an attractive tumor-specific treatment target.
The compound Zolbetuximab was developed in Germany more than a decade ago and has since been extensively investigated through all stages of testing right up to clinical use in patients. It is given as an intravenous infusion to people with advanced gastric cancer in combination with chemotherapy. It then travels through the bloodstream to the tumour cells that express claudin 18.2, where it binds to them and triggers an immune response that helps kill the tumour cells.
Translation: Matthew Rockey
Professor Florian Lordick
Director of the University Cancer Center Leipzig und
Spokesman of the Board of the Cancer Center Central Germany (CCCG)
Email: direktion.uccl@medizin.uni-leipzig.de
Tel: +49 341 97-12200
Web: http://www.krebszentrum-leipzig.de, https://www.mitteldeutsches-krebszentrum.de/
Original publication in The New England Journal of Medicine: Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. DOI: 10.1056/NEJMc2409512
https://www.nejm.org/doi/10.1056/NEJMc2409512
The substance is given as an intravenous infusion to people with advanced gastric cancer in combinat ...
Photo: Colourbox
Colourbox
Prof. Florian Lordick.
Photo: Stefan Straube
UKL
Criteria of this press release:
Journalists, Scientists and scholars
Medicine
transregional, national
Research results, Scientific Publications
English
The substance is given as an intravenous infusion to people with advanced gastric cancer in combinat ...
Photo: Colourbox
Colourbox
Prof. Florian Lordick.
Photo: Stefan Straube
UKL
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
